Coronary CT angiography has proven to be a boon to radiologists and cardiologists in private practice. With a high negative predictive value, it can easily rule out coronary artery disease in patients with nondiagnostic electrocardiograms. For cardiologists in particular, CTA can help offset declining reimbursements associated with catheter procedures and nuclear medicine tests. But some cardiologists resist.
Coronary CT angiography has proven to be a boon to radiologists and cardiologists in private practice. With a high negative predictive value, it can easily rule out coronary artery disease in patients with nondiagnostic electrocardiograms. For cardiologists in particular, CTA can help offset declining reimbursements associated with catheter procedures and nuclear medicine tests. But some cardiologists resist.
"The CT coronary angiogram is demonstrating its usefulness as a noninvasive alternative to conventional catheter angiography that is capable of documenting both hard- and soft-plaque formations. With recent emphasis being placed on data surrounding the study of soft-plaque formation and its relationship to acute myocardial infarction, it seems CT angiography will become an integral tool in the prevention and treatment of coronary artery disease and acute myocardial infarction.
"Not every cardiologist is ready to roll over for coronary CTA, however. The invasive cardiologists want to know how accurate it is. Additionally, they are concerned it will take some of their income away. We see that. We tell them that cardiac CT will actually help to increase invasive procedures. Even hospitals are concerned about the potential loss of money from fewer catheter procedures. They are resistant to adopting CTA.
"Nationally, the statistics show that almost half of all cardiac cath procedures are negative, meaning they do not result in stenting or bypass surgery. If you can evaluate patients noninvasively, you're saving thousands of dollars, as well as diminishing real but low risks of mortality and morbidity."
-Dr. Steven M. Strobbe, executive physician and CEO of Florida Institute for Advanced Diagnostic Imaging in Port Richey
What is the Best Use of AI in CT Lung Cancer Screening?
April 18th 2025In comparison to radiologist assessment, the use of AI to pre-screen patients with low-dose CT lung cancer screening provided a 12 percent reduction in mean interpretation time with a slight increase in specificity and a slight decrease in the recall rate, according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can CT-Based AI Radiomics Enhance Prediction of Recurrence-Free Survival for Non-Metastatic ccRCC?
April 14th 2025In comparison to a model based on clinicopathological risk factors, a CT radiomics-based machine learning model offered greater than a 10 percent higher AUC for predicting five-year recurrence-free survival in patients with non-metastatic clear cell renal cell carcinoma (ccRCC).
Could Lymph Node Distribution Patterns on CT Improve Staging for Colon Cancer?
April 11th 2025For patients with microsatellite instability-high colon cancer, distribution-based clinical lymph node staging (dCN) with computed tomography (CT) offered nearly double the accuracy rate of clinical lymph node staging in a recent study.